Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nordhealth AS has the GF Score of 72, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Nordhealth AS
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Nordhealth AS (OSL:NORDH) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Nordhealth AS GF Score Related Terms
OSL:NORDH vs VEEV, BTSG, TEM: GF Score Comparison
For the Health Information Services subindustry, Nordhealth AS's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nordhealth AS GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nordhealth AS's GF Score distribution charts can be found below:
* The bar in red indicates where Nordhealth AS's GF Score falls into.
Nordhealth AS (OSL:NORDH) has a GF Score of 72 as of Jul. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nordhealth AS and its competitors. This is 213% above median its historical median of 23.00. Over the past decade, Nordhealth AS's GF Score has ranged from 13.00 to 75.00.
Is Nordhealth AS's GF Score too high?
Nordhealth AS's current GF Score of 72 is 213% above median its 10-year median of 23.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 75.00. Overall, Nordhealth AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nordhealth AS's GF Score compare to VEEV and BTSG?
Nordhealth AS's GF Score of 72 can be compared against companies in the Healthcare Providers & Services industry. Historically, Nordhealth AS's own GF Score has ranged from 13.00 to 75.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nordhealth AS and its competitors. Nordhealth AS's current GF Score is 72, which is 213% above median its own 10-year median of 23.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nordhealth AS stock overvalued right now?
Based on GuruFocus' analysis, Nordhealth AS (OSL:NORDH) is currently considered Significantly Undervalued. The stock's GF Value™ is kr39.33, compared to a current price of kr25.00 — trading 36.4% below its estimated fair value. The current GF Score is 72, which is 213% above median its 10-year median of 23.00. Nordhealth AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Nordhealth AS (OSL:NORDH), the current GF Score is 72 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nordhealth AS (OSL:NORDH) Overvalued in 2026?
Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued.
The current stock price of kr25.00 is trading 36.4% below its estimated GF Value™ of kr39.33.
GuruFocus considers Nordhealth AS to be Significantly Undervalued.
Key valuation signals for OSL:NORDH:
GF Score: 72 (213% above median its 10-year median of 23.00)
GF Value™: kr39.33 vs. price of kr25.00 (36.4% below fair value)
No single metric tells the full story. See the OSL:NORDH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.
72GF Score
Get the complete analysis for OSL:NORDH
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:NORDH has been successfully added to your 
